Whistle-Blower Is Awarded $1.6 Million A former drug sales representative who became a whistle-blower has been awarded $1.6 million for bringing a drug marketing fraud to light, despite efforts by the Justice Department to prevent his receiving the money.
But in the same ruling, a federal judge criticized the former sales representative, James Marchese, for not bringing the scheme to light earlier, given that he thought that cancer patients were being harmed as a result of the fraud.
Mr. Marchese’s case, which was described in an October article in The New York Times, drew attention because prosecutors had rarely argued that a whistle-blower should be denied any portion of the funds recovered from a lawsuit he or she initiated.
To do so, prosecutors must show that a whistle-blower was the planner or initiator of the scheme involved; otherwise he or she is legally entitled to receive 15 to 25 percent of any funds recovered by the government. The precise figure is determined by a whistle-blower’s contribution to the case.
In a ruling after a two-day hearing last month in Seattle, Judge Marsha J. Pechman of Federal District Court found that prosecutors had failed to prove that Mr. Marchese was the initiator of a scheme at his former employer, Cell Therapeutics. In April, the company agreed to pay $10.5 million to settle charges that it had bilked Medicare out of that much money in connection with the sale of a cancer drug, Trisenox.
At the hearing, Mr. Marchese and his lawyers argued that he should receive 25 percent, about $2.6 million. Among other things, Mr. Marchese maintained that the government would never have had a case without him.
NY Times - Read Full ArticleWhy ask why?